Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?
The type 5 metabotropic glutamate receptor, mGlu5, has been proposed as a potential therapeutic target for the treatment of several neurodegenerative diseases. In preclinical neurodegenerative disease models, novel allosteric modulators have been shown to improve cognitive performance and reduce dis...
Saved in:
Main Authors: | Rebecca F. Budgett (Author), Geor Bakker (Author), Eugenia Sergeev (Author), Kirstie A. Bennett (Author), Sophie J. Bradley (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metabotropic Glutamate Receptors and Neurological/Psychiatric Disorders
Published: (2019) -
Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs
by: Carolina eMuguruza, et al.
Published: (2016) -
Metabotropic glutamate receptor 5 (mGluR5) regulates bladder nociception
by: Crock Lara W, et al.
Published: (2012) -
In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5
by: Sarah Beggiato, et al.
Published: (2018) -
Shedding of Microvesicles from Microglia Contributes to the Effects Induced by Metabotropic Glutamate Receptor 5 Activation on Neuronal Death
by: Martina Beneventano, et al.
Published: (2017)